LAS VEGAS, March 26, 2015 /PRNewswire/ -- Zimmer Holdings,
Inc. (NYSE and SIX: ZMH) announced today the debut of a new mobile
app designed to serve as a feature-rich resource for patients of
its Gel-One® Hyaluronate product.
For those experiencing knee pain, the Gel-One Patient App
from Zimmer provides valuable information about the causes of knee
pain and helps them understand more about the potential of
Gel-One Hyaluronate as a safe and simple non-surgical
treatment option. For those who have had a Gel-One
Hyaluronate injection or are looking to get one, the app offers a
number of features, including educational resources on
Gel-One Hyaluronate, a location-based surgeon finder, and a
pain tracker that enables patients to record their pain level on a
daily basis.
"Just like the Gel-One product itself, this app is about
empowering patients and helping them learn more about the
outstanding non-surgical options at their disposal," said
Seth Middleton, Director, Sales and
Marketing, Early Intervention. "By providing a simple user
interface and the ability to track pain and activity levels, the
new Gel-One Patient App can give patients a streamlined and
centralized experience – and help them better understand how
Gel-One Hyaluronate works."
The Gel-One Patient App is out today and available in
both the Apple iTunes App Store and
the Google Play Store. For more information or to download, visit
geloneapp.com.
Gel-One® is a registered trademark of Seikagaku
Corporation.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops,
manufactures and markets orthopaedic reconstructive, spinal and
trauma devices, dental implants, and related surgical
products. Zimmer has operations in more than 25 countries
around the world and sells products in more than 100
countries. Zimmer's 2014 sales were approximately
$4.7 billion. The Company
is supported by the efforts of more than 9,000 employees
worldwide. More information about Zimmer is available at
www.zimmer.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based upon
the current beliefs and expectations of Zimmer's management and are
subject to significant risks and uncertainties that could cause
actual outcomes and results to differ materially. These risks
and uncertainties include, but are not limited to: future test
results or patient experiences being inconsistent with test
findings to date; actions of regulatory bodies or other
governmental authorities; changes in laws and regulations;
competitive developments; and other risks and uncertainties
described in Zimmer's periodic reports filed with the U.S.
Securities and Exchange Commission. Zimmer disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be set forth in Zimmer's periodic
reports. Readers of this communication are cautioned not to
place undue reliance on these forward-looking statements, since,
while management believes the assumptions on which the
forward-looking statements are based are reasonable, there can be
no assurance that these forward-looking statements will prove to be
accurate.
Logo -
http://photos.prnewswire.com/prnh/20131216/MM33947LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/zimmer-launches-new-patient-education-and-engagement-mobile-app-for-gel-one-hyaluronate-300056444.html
SOURCE Zimmer Holdings, Inc.